News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
kalkine.ca Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bausch Health Companies (NYSE: BHC) had quite a scorching July as far as its stock was concerned. It was bookended by a regulatory win in Canada for the pharmaceutical conglomerate and a beat-and-raise quarterly earnings report. This propelled the stock to a nearly 40% …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Dimensional Fund Advisors LP significantly increased its stake in Bausch Health Cos Inc. by 10.8% in the first quarter of 2026, acquiring 350,823 additional shares to reach a total of 3.6 million shares. Other institutional investors also raised their positions, with institutions now owning …
This page provides comprehensive financial data for Bausch Health Companies Inc. (BHC.TO), including its current stock price, historical performance, key financial statistics, and analyst ratings. The company, which operates as a diversified specialty pharmaceutical and medical device firm, saw its stock close at 8.28 …
Bausch Health CEO Thomas J. Appio has been appointed to the board of directors of its subsidiary Bausch + Lomb Corporation. This move, along with the appointment of three other new directors and the resignation of four existing ones, aligns with Bausch Health's significant …
Thomas J. Appio, CEO of Bausch Health Companies Inc., has been appointed to the board of directors of Bausch + Lomb Corporation, a subsidiary of Bausch Health. This appointment was effective August 5, 2026. The announcement was made by Bausch Health Companies Inc.
Bausch + Lomb (NYSE/TSX: BLCO) announced changes to its Board of Directors, with four new appointments effective August 5, 2026, at the request of majority owner Bausch Health Companies Inc. The company also reaffirmed its full-year 2026 guidance for revenue between $5.440 billion and …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Bausch Health announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb, effective August 5, 2026. This appointment, along with three other new directors, was requested by Bausch Health, which indirectly holds approximately 87% of …
Bausch Health Companies Inc. (BHC) is a healthcare company with a diversified portfolio showing a potential upside of 7.14%. Despite mixed valuation metrics and cautious analyst ratings, the company boasts solid revenue growth and substantial free cash flow. Investors are advised to monitor technical …
Bausch Health Companies (BHC) stock has seen a significant surge, climbing 56% over five consecutive trading days and adding $923 million to its market value. While this streak shows strong near-term momentum and attention from the market, investors are encouraged to re-evaluate the underlying …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Bausch Health Companies Inc. (BHC) saw its stock surge by 13.62% after reporting strong Q2 results, crushing consensus estimates for EPS and revenue, and lifting its 2026 outlook. The company demonstrated its 13th consecutive quarter of revenue and adjusted EBITDA growth, driven by strong …
Bausch Health Companies Inc. has published its 2026 Q2 earnings call presentation. The company reported an EPS of $1.26, beating estimates by $0.25, and revenue of $2.85 billion, surpassing expectations by $192.90 million with a 12.73% year-over-year increase. This presentation is available for investors …
Bausch Health Companies Inc. (BHC) surged by 13.62% following stronger-than-expected Q2 earnings, beating consensus on both EPS and revenue, marking its 13th consecutive quarter of revenue and adjusted EBITDA growth. The company also reported strong operating cash flow and reduced net debt, leading to …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Bausch Health Companies Inc. has published its 2026 Q2 earnings call presentation. The company reported an EPS of $1.26, beating estimates by $0.25, and revenue of $2.85 billion, surpassing expectations by $192.90 million with a 12.73% year-over-year increase. This presentation is available for investors …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Bausch Health Companies Inc. (BHC) saw its stock jump by 11.53% due to strong Q2 2026 earnings, beating analyst expectations for both EPS and revenue. This marks the 13th consecutive quarter of revenue and adjusted EBITDA growth for the company, signaling a significant turnaround …
Bausch Health Companies Inc. reported strong Q2 2026 results with revenue of $2.85 billion, an increase from $2.53 billion year-over-year. Diluted EPS rose to $0.68 from $0.40, and net income attributable to the company significantly increased to $258 million. This growth was driven by …
(RTTNews) - Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Bausch Health (NYSE: BHC) reported a net loss of $1.17 billion for the first half of 2026, primarily due to a $1.43 billion goodwill impairment in its Salix reporting unit. This impairment followed failed Phase 3 clinical trials for a rifaximin formulation. Despite the …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Bausch Health Companies Inc. BHC reported second-quarter 2026 adjusted earnings of $1.26 per share, up 40% year over year. The figure beat the Zacks Consensus Estimate of 96 cents. Revenues increased 13% year over year to $2.85 billion and surpassed the Zacks Consensus Estimate …
Bausch Health (BHC) reported better-than-expected Q2 financials and raised its full-year outlook, leading to a significant stock gain of over 27% on Thursday. This performance marks one of the company's best intraday rallies in nearly a decade. The Canadian drugmaker announced $2.9 billion in …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Bausch Health Companies Inc. (BHC.TO) was Thursday's top gainer in Canadian stock markets, rising 12.18% to close at C$7.32. The Capital Markets sector broadly led Thursday's gains, increasing by 2.22%. Trading volume was robust, with 364.57 million shares changing hands, exceeding the 10-day average.
This article provides a comprehensive stock analysis of Bausch Health Companies Inc (BHC) by Tradingkey. It highlights the company's stable fundamentals, high growth potential, and current "Hold" rating from analysts with an upside space targeting 7.17. Despite high institutional ownership and a recent shift …
Key Points Interested in Bausch Health Cos Inc.? Here are five stocks we like better. Bausch Health raised its full-year outlook after reporting strong second-quarter growth: excluding Bausch + Lomb, revenue rose 16% to $1.458 billion and adjusted EBITDA increased 28% to $865 million. …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Bausch Health (BHC) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …
Bausch Health (BHC) reported $2.85 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.7%. EPS of $1.26 for the same period compares to $0.90 a year ago. The reported revenue represents a surprise of +7.62% over the Zacks …
Search by ticker symbol or company name and select a result to open its chart.